[go: up one dir, main page]

AR085252A1 - Metodo de produccion de derivado de dihidrobenzofurano opticamente activo - Google Patents

Metodo de produccion de derivado de dihidrobenzofurano opticamente activo

Info

Publication number
AR085252A1
AR085252A1 ARP120100517A ARP120100517A AR085252A1 AR 085252 A1 AR085252 A1 AR 085252A1 AR P120100517 A ARP120100517 A AR P120100517A AR P120100517 A ARP120100517 A AR P120100517A AR 085252 A1 AR085252 A1 AR 085252A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
formula
group
compound represented
optically active
Prior art date
Application number
ARP120100517A
Other languages
English (en)
Inventor
Mitsuhisa Yamano
Mitsutaka Goto
Takeshi Kajiwara
Hiroyuki Maeda
Takahiro Konishi
Misayo Sera
Yuichiro Kondo
Seiji Yamasaki
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of AR085252A1 publication Critical patent/AR085252A1/es

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/22—Organic complexes
    • B01J31/2282—Unsaturated compounds used as ligands
    • B01J31/2295—Cyclic compounds, e.g. cyclopentadienyls
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • C07C215/30—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings containing hydroxy groups and carbon atoms of six-membered aromatic rings bound to the same carbon atom of the carbon skeleton
    • C07C215/32—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings containing hydroxy groups and carbon atoms of six-membered aromatic rings bound to the same carbon atom of the carbon skeleton containing hydroxy groups and carbon atoms of two six-membered aromatic rings bound to the same carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00—Preparation of sulfones; Preparation of sulfoxides
    • C07C315/04—Preparation of sulfones; Preparation of sulfoxides by reactions not involving the formation of sulfone or sulfoxide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/18—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/86—Benzo [b] furans; Hydrogenated benzo [b] furans with an oxygen atom directly attached in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/006—Palladium compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F17/00—Metallocenes
    • C07F17/02—Metallocenes of metals of Groups 8, 9 or 10 of the Periodic Table
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/50—Organo-phosphines
    • C07F9/5018—Cycloaliphatic phosphines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/50—Organo-phosphines
    • C07F9/5004—Acyclic saturated phosphines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/50—Organo-phosphines
    • C07F9/5022—Aromatic phosphines (P-C aromatic linkage)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/50—Organo-phosphines
    • C07F9/5027—Polyphosphines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/50—Organo-phosphines
    • C07F9/5031—Arylalkane phosphines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6568—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus atoms as the only ring hetero atoms
    • C07F9/65683—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus atoms as the only ring hetero atoms the ring phosphorus atom being part of a phosphine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Furan Compounds (AREA)

Abstract

Reivindicación 1: Un método de producción de una forma ópticamente activa de un compuesto representado por la fórmula (1) en donde R3 es un grupo hidroxi o un grupo alcoxi C1-6 opcionalmente sustituido, o una de sus sales, que comprende una etapa de producción de una forma ópticamente activa de un compuesto representado por la fórmula (2) en donde R1 es un grupo hidroxi o un grupo alcoxi C1-6 opcionalmente sustituido; y X es un átomo de halógeno, un grupo hidroxi o un grupo alcoxi C1-6 opcionalmente sustituido; o una de sus sales, al someter un compuesto representado por la fórmula (1) en donde cada símbolo es como se definió con anterioridad, o una de sus sales, a una reacción de hidrogenación asimétrica en presencia de un complejo de rutenio.Reivindicación 9: Una sal de una forma ópticamente activa de un compuesto representado por la fórmula (4) en donde X es un átomo de halógeno, un grupo hidroxi o un grupo alcoxi C1-6 opcionalmente sustituido, en donde una base orgánica de la sal es (i) una forma ópticamente activa de un compuesto representado por la fórmula (5) en donde RB1a es un grupo arilo C6-14 opcionalmente sustituido o un grupo aralquilo C7-13 opcionalmente sustituido; y RB4 es un grupo alquilo C1-6 opcionalmente sustituido, o (ii) una forma ópticamente activa de un compuesto representado por la fórmula (6) en donde RB2a es un átomo de hidrógeno o un grupo arilo C6-14 opcionalmente sustituido; RB3a es un grupo arilo C6-14 opcionalmente sustituido o un grupo alquilo C1-6 opcionalmente sustituido; RB5 es un grupo alquilo C1-6 opcionalmente sustituido o un grupo arilo C6-14 opcionalmente sustituido; RB6 es un átomo de hidrógeno o un grupo alquilo C1-6 opcionalmente sustituido; o RB3a y RB5 forman opcionalmente, junto con el átomo de carbono adyacente, un anillo de 4 a 6 miembros opcionalmente sustituido (dicho anillo de 4 a 6 miembros está opcionalmente fusionado con un anillo benceno opcionalmente sustituido); o RB5 y RB6 forman opcionalmente, junto con el átomo de nitrógeno y átomo de carbono adyacente, un anillo de 4 a 6 miembros opcionalmente sustituido. Reivindicación 12: Un complejo de rutenio representado por la fórmula: RuCl2(L)(dmf)n en donde L es una forma ópticamente activa de 1,2-bis(2,5-diisopropilfosforano)benceno; dmf es N,N-dimetilformamida; y n es un número entero de uno o más. Reivindicación 15: Un compuesto representado por la fórmula (7) en donde Y es un grupo saliente, o una de sus sales. Reivindicación 18: Un compuesto representado por la fórmula (8) en donde Z es un átomo de halógeno, o una de sus sales. Reivindicación 21: Un cristal de ácido [(3S)-6-({2’,6’-dimetil-4’-[3-(metilsulfonil)propoxi]bifenil-3-il}metoxi)-2,3-dihidro-1-benzofuran-3-il]acético, que muestra un patrón de difracción de polvos por rayos X que tiene picos característicos en el espaciado en la rejilla (d) de aproximadamente 19,24 ± 0,2, 18,79 ± 0,2, 6,35 ± 0,2, 5,37 ± 0,2, 4,91 ± 0,2 y 4,83 ± 0,2 Å por difracción de polvos por rayos X.
ARP120100517A 2011-02-17 2012-02-16 Metodo de produccion de derivado de dihidrobenzofurano opticamente activo AR085252A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2011032610 2011-02-17

Publications (1)

Publication Number Publication Date
AR085252A1 true AR085252A1 (es) 2013-09-18

Family

ID=45841559

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120100517A AR085252A1 (es) 2011-02-17 2012-02-16 Metodo de produccion de derivado de dihidrobenzofurano opticamente activo

Country Status (24)

Country Link
US (1) US8952185B2 (es)
EP (1) EP2675774A1 (es)
JP (1) JP5945545B2 (es)
KR (1) KR20140015371A (es)
CN (1) CN103492348A (es)
AR (1) AR085252A1 (es)
AU (1) AU2012218401A1 (es)
BR (1) BR112013020634A2 (es)
CA (1) CA2827271A1 (es)
CL (1) CL2013002356A1 (es)
CO (1) CO6761376A2 (es)
CR (1) CR20130407A (es)
DO (1) DOP2013000188A (es)
EA (1) EA201391180A1 (es)
EC (1) ECSP13012855A (es)
IL (1) IL227879A0 (es)
MA (1) MA34965B1 (es)
MX (1) MX2013009526A (es)
PH (1) PH12013501718A1 (es)
SG (1) SG192645A1 (es)
TN (1) TN2013000347A1 (es)
TW (1) TW201245169A (es)
UY (1) UY33913A (es)
WO (1) WO2012111849A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103145663B (zh) * 2013-03-01 2016-03-23 上海高准医药有限公司 (s)-2-(2,3-二氢苯并呋喃-3-基)乙酸衍生物，其制备方法及其在医药上的应用
CN104250239B (zh) * 2013-06-29 2016-09-07 山东轩竹医药科技有限公司 芳香多环羧酸衍生物
CN104370864B (zh) * 2013-08-14 2016-04-13 成都苑东生物制药股份有限公司 一种2-(6-羟基-2,3-二氢苯并呋喃-3-基)乙腈化合物和以该化合物制备tak-875药物的方法
JP6533778B2 (ja) * 2013-09-26 2019-06-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｇｐｒ４０アゴニストとしてのインダニルオキシジヒドロベンゾフラニル酢酸誘導体を調製するための方法および中間体
HK1221465A1 (zh) 2013-11-14 2017-06-02 Cadila Healthcare Limited 新型杂环化合物
EP3076959B1 (en) 2013-12-04 2018-07-04 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
CN104177320B (zh) * 2014-08-27 2016-03-02 广东东阳光药业有限公司 一种脲取代联苯类化合物及其组合物及用途
EP3272345B1 (en) * 2015-03-19 2019-10-16 Daiichi Sankyo Company, Limited Solid preparation containing antioxidant agent
CN107427483B (zh) 2015-03-19 2021-06-29 第一三共株式会社 含有着色剂的固体制剂
CN105418563B (zh) * 2015-12-28 2017-11-10 山东大学 Tak‑875类似物及其制备方法与应用
CN107543872B (zh) * 2016-06-29 2022-03-08 南京长澳医药科技有限公司 通过手性高效液相色谱法分离测定甲苯磺酸依度沙班水合物与其异构体杂质的方法
CN110088089B (zh) 2016-10-25 2023-08-29 勃林格殷格翰国际有限公司 苄基氨基吡啶基环丙烷甲酸、药物组合物及其用途
WO2018138027A1 (en) 2017-01-26 2018-08-02 Boehringer Ingelheim International Gmbh Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceuticalcompositions and uses thereof
CN106977478B (zh) * 2017-04-21 2019-04-09 山东大学 一种2-(6-羟基-2,3-二氢苯并呋喃-3-基)乙酸甲酯的手性拆分方法
CR20200347A (es) 2018-02-13 2020-09-23 Gilead Sciences Inc Inhibidores pd-1/pd-l1
KR102591947B1 (ko) 2018-04-19 2023-10-25 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
PT3820572T (pt) 2018-07-13 2023-11-10 Gilead Sciences Inc Inibidores pd-1/pd-l1
ES2943883T3 (es) 2018-07-30 2023-06-16 Daiichi Sankyo Co Ltd Formulación de fármaco sólido que contiene estabilizador
JP7158577B2 (ja) 2018-10-24 2022-10-21 ギリアード サイエンシーズ， インコーポレイテッド Ｐｄ－１／ｐｄ－ｌ１阻害剤
PH12022550852A1 (en) 2019-10-07 2023-05-03 Kallyope Inc Gpr119 agonists
CA3173731A1 (en) 2020-02-28 2021-09-02 Kallyope, Inc. Gpr40 agonists
KR20230012597A (ko) 2020-05-19 2023-01-26 칼리오페, 인크. Ampk 활성화제
AU2021297323A1 (en) 2020-06-26 2023-02-16 Kallyope, Inc. AMPK activators
CN114539168B (zh) * 2020-11-27 2023-11-17 武汉大学 一种合成Piragliatin及其类似物的方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1072649C (zh) 1995-09-13 2001-10-10 武田药品工业株式会社 苯并氧杂吖庚因化合物,其生产方法和用途
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
US20030187023A1 (en) 2000-07-17 2003-10-02 Keiji Kubo Sulfone derivatives, process for their production and use thereof
PE20040609A1 (es) 2002-11-01 2004-10-29 Takeda Pharmaceutical Compuestos heterociclicos aromaticos como promotores de un factor neurotrofico
US7960369B2 (en) 2002-11-08 2011-06-14 Takeda Pharmaceutical Company Limited Receptor function regulator
CA2507026A1 (en) 2002-11-22 2004-06-10 Takeda Pharmaceutical Company Limited Imidazole derivatives, their production and use
WO2004106276A1 (ja) 2003-05-30 2004-12-09 Takeda Pharmaceutical Company Limited 縮合環化合物
US7534887B2 (en) 2003-09-30 2009-05-19 Takeda Pharmaceutical Company Limited Thiazoline derivative and use of the same
JP4769082B2 (ja) 2003-12-17 2011-09-07 武田薬品工業株式会社 ウレア誘導体、その製造法及び用途
TW200523247A (en) 2003-12-25 2005-07-16 Takeda Pharmaceutical 3-(4-benzyloxyphenyl) propanoic acid derivatives
JP4855777B2 (ja) 2003-12-26 2012-01-18 武田薬品工業株式会社 フェニルプロパン酸誘導体
US7786165B2 (en) 2004-03-15 2010-08-31 Takeda Pharmaceutical Company Limited Aminophenylpropanoic acid derivative
EP1731505B1 (en) 2004-03-30 2015-01-14 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
GB0428101D0 (en) * 2004-12-23 2005-01-26 Astrazeneca Ab Chemical Processes & Intermediates
JP5094394B2 (ja) 2005-04-20 2012-12-12 武田薬品工業株式会社 縮合複素環化合物
EP1911738A4 (en) 2005-07-29 2009-12-16 Takeda Pharmaceutical COMPOUND OF PHENOXYALKANOIC ACID
JP5084503B2 (ja) 2005-07-29 2012-11-28 武田薬品工業株式会社 シクロプロパンカルボン酸化合物
MX2008001386A (es) 2005-08-10 2008-04-07 Takeda Pharmaceutical Agente terapeutico para diabetes.
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
ES2450081T3 (es) * 2006-06-27 2014-03-21 Takeda Pharmaceutical Company Limited Compuestos cíclicos condensados como moduladores del receptor GPR40
WO2008047821A1 (en) 2006-10-18 2008-04-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
CN101573357B (zh) 2006-10-19 2013-01-23 武田药品工业株式会社 吲哚化合物
WO2008093639A1 (ja) 2007-01-29 2008-08-07 Takeda Pharmaceutical Company Limited ピラゾール化合物
AU2008215490A1 (en) 2007-02-09 2008-08-21 Takeda Pharmaceutical Company Limited Fused ring compounds as partial agonists of PPAR-gamma
US8455661B2 (en) 2007-02-18 2013-06-04 University Of Florida Research Foundation, Inc. Catalysts containing N-heterocyclic carbenes for enantioselective synthesis
US8318746B2 (en) 2007-04-27 2012-11-27 Takeda Pharmaceutical Company Limited Nitrogen-containing five-membered heterocyclic compound
JP2011502958A (ja) 2007-06-19 2011-01-27 武田薬品工業株式会社 グルコキナーゼ活性化インダゾール化合物
WO2010143733A1 (en) 2009-06-09 2010-12-16 Takeda Pharmaceutical Company Limited Novel fused cyclic compound and use thereof
JP5129209B2 (ja) 2009-08-03 2013-01-30 ゴールドフラッグ株式会社 ブラジャー及び該ブラジャー付き下着とこれをインナーとしたアウター

Also Published As

Publication number Publication date
WO2012111849A1 (en) 2012-08-23
DOP2013000188A (es) 2013-11-30
EA201391180A1 (ru) 2014-01-30
KR20140015371A (ko) 2014-02-06
IL227879A0 (en) 2013-09-30
TW201245169A (en) 2012-11-16
JP5945545B2 (ja) 2016-07-05
MX2013009526A (es) 2013-10-01
EP2675774A1 (en) 2013-12-25
JP2014513036A (ja) 2014-05-29
CR20130407A (es) 2013-10-09
BR112013020634A2 (pt) 2016-10-25
CA2827271A1 (en) 2012-08-23
ECSP13012855A (es) 2013-10-31
SG192645A1 (en) 2013-09-30
MA34965B1 (fr) 2014-03-01
CO6761376A2 (es) 2013-09-30
UY33913A (es) 2012-09-28
CN103492348A (zh) 2014-01-01
AU2012218401A1 (en) 2013-09-05
TN2013000347A1 (en) 2015-01-20
PH12013501718A1 (en) 2013-10-07
US20130345444A1 (en) 2013-12-26
CL2013002356A1 (es) 2014-01-03
US8952185B2 (en) 2015-02-10

Similar Documents

Publication Publication Date Title
AR085252A1 (es) Metodo de produccion de derivado de dihidrobenzofurano opticamente activo
BR112014001520A2 (pt) processo para a produção de composto de benzo[b]tiofeno
BR112012011689A2 (pt) processo para a produção de etexilato de dabigatran
CO6270225A2 (es) Un compuesto novedoso de anillo fusionado que presenta actividad inhibitoria de faah
BR112013001245A2 (pt) método de produção de ingenol-3-angelato
CY1121617T1 (el) Ενδιαμεσο προϊον για συνθεση της 1-(2-δεοξυ-2-φθορο-4-θειο-βητα-d-αραβινοφουρανοζυλ)κυτοσινης, ενδιαμεσο προϊον για συνθεση του θειονουκλεοζιδιου, και μεθοδοι για παραγωγη αυτων των ενδιαμεσων προϊοντων
CR20150192A (es) Moduladores de quinolinilo unidos a fenilo de ror-gamma-t
BR112014024493A2 (pt) método para a produção enzimática de isoprenol usando mevalonato como substrato
BR112015031211A2 (pt) Método para a produção de composições orgânicas de oxihidrogênico e co2 através de acetoacetil-coa-redutase como produto intermediário
BR112014017804A8 (pt) Método para a produção do p-xileno e/ou do p-toluakdeído
FR2983198B1 (fr) Procede de preparation de derives de 5-amino-benzoyl-benzofurane
BR112015010557A2 (pt) método para a produção de fenol a partir de fontes renováveis por meio de fermentação.
BR112015032403A2 (pt) processo para produzir um tetraidrofurano-(thf)-2,5-dicarbaldeído, tetraidrofurano (thf)-2,5-dicarbaldeído, método para preparar um composto derivado furânico de um tetraidrofurano (thf)-2,5-dialdeído, composto derivado furânico transformado por oxidação, composto derivado furânico transformado por modificação de base de schiff, composto derivado furânico transformado por sulfonamidação, composto derivado furânico transformado por síntese de mono- e diacetais, composto derivado furânico transformado por aminação redutora, composto derivado furânico transformado por condensação aldólica, composto derivado furânico transformado por formação de oxima, e, composto derivado furânico
BR112013020864A2 (pt) métodos para sintetizar derivados de precursor z de molibdopterina
BR112015020725A2 (pt) ariloxi-ftalocianinas de metais do grupo iv
AR068062A1 (es) Sulfonas ciclicas sustituidas por amino- bencilo utiles como inhibidores de bace
MX2013004872A (es) Procesos para preparar un fenilciclohexano.
MX351408B (es) Métodos para producir 1,5,7-triazabiciclo [4.4.0] dec-5-eno mediante la reacción de una carbodiimida disustituida y dipropilen triamina.
AR087345A1 (es) Metodos para la preparacion de compuestos de tiofeno
BR112015031722A2 (pt) método de preparação de 4-benzil-1-fenetil-piperazina-2,6-diona, e intermediário e método de preparação dos mesmos
EA201300884A1 (ru) Способ получения нового антибактериального лекарственного средства на основе рекомбинантного полипептида
BR112012022928A2 (pt) beta-hidroxialquilamidas, processo para sua produção, bem como seu uso
AR070935A1 (es) Proceso catalitico para hidrogenacion asimetrica
ES2721446T3 (es) Método para producir un compuesto de éster del ácido ciclopropano carboxílico ópticamente activo, un complejo de cobre asimétrico y un compuesto de salicilidenoaminoalcohol ópticamente activo
UY33507A (es) Proceso para la preparacion de sales de enolato de 4-fluoro-2-hidroximetileno-3-oxo-butiratos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal